Streetbeat News

Analyst Ratings

SONO

Rosenblatt analyst Steve Frankel reiterated a Buy rating on Sonos (NASDAQ:SONO) and maintained a $24 price target, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:56 am

CHH

Baird analyst Michael Bellisario has maintained an Outperform rating on Choice Hotels Intl (NYSE:CHH) and increased the price target from $138 to $140.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:55 am

NVTS

Rosenblatt analyst Kevin Cassidy has reiterated a Buy rating on Navitas Semiconductor (NASDAQ:NVTS) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:54 am

MLCO

B of A Securities analyst Ronald Leung has maintained a Neutral rating on Melco Resorts and Entertainment (MLCO) and lowered the price target from $10 to $8.4.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:53 am

MSTR

Canaccord Genuity analyst Joseph Vafi has maintained a Buy rating on MicroStrategy (NASDAQ:MSTR) and increased the price target from $975 to $1810.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:51 am

WVE

Mizuho analyst Salim Syed has maintained a Buy rating on WAVE Life Sciences (NASDAQ:WVE) and increased the price target from $10 to $19, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:50 am

VTYX

Ventyx Biosciences' stock price is on the rise following upgrades from Oppenheimer and Wells Fargo. Oppenheimer upgraded Ventyx from Perform to Outperform with a $12 price target, while Wells Fargo moved its rating from Equal-Weight to Overweight and set a new price target of $16, up from $7.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:48 am

LEG

Piper Sandler analyst Peter Keith maintains an Underweight rating on Leggett & Platt (NYSE:LEG) and lowers the price target from $18 to $16.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:48 am

PCVX

Mizuho analyst Salim Syed has maintained a Buy rating on Vaxcyte (NASDAQ:PCVX) and increased the price target from $69 to $113, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:47 am

ONON

Telsey Advisory Group analyst Joseph Feldman has reiterated an Outperform rating on On Holding (NYSE:ONON) and maintained a $37 price target.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:46 am